GSM5218318[Accession] - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Search results

Items: 4

Select item 2001710741.

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Methylation profiling by array; Other; Methylation profiling by high throughput sequencing

4 related Platforms
88 Samples

Download data: BED, BW, HIC, IDAT, NARROWPEAK, TXT

Series

Accession:: GSE171074

ID:: 200171074

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001710732.

Epigenetic therapy suppresses tumour growth by rewiring ER-mediated long-range chromatin interactions in ER+ endocrine-resistant breast cancer [RNA-seq]

(Submitter supplied) Here we investigate the impact of epigenetic therapy with Decitabine in endocrine-resistant ER+ breast cancer by using patient-derived xenograft (PDX) models. Decitabine treatment restrained tumour growth, inhibited cell proliferation and resulted in significant loss of DNA methylation, particularly at enhancers and repetitive elements. Systematic integration of matched in situ Hi-C / PCHi-C, EPIC, RNA-seq and ChIP–seq datasets revealed widespread differences in epigenome regulation and enhancer-promoter communication with Decitabine. more...